Thrombin receptor-activating peptides (TRAPs): Investigation of bioactive conformations via structure-activity, spectroscopic, and computational studies

被引:30
|
作者
Ceruso, MA
McComsey, DF
Leo, GC
Andrade-Gordon, P
Addo, MF
Scarborough, RM
Oksenberg, D
Maryanoff, BE [1 ]
机构
[1] RW Johnson Pharmaceut Res Inst, Spring House, PA 19477 USA
[2] COR Therapeut Inc, San Francisco, CA 94080 USA
关键词
peptides; receptor agonists; NMR; circular dichroism; molecular modeling;
D O I
10.1016/S0968-0896(99)00180-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The thrombin receptor (PAR-1) is an unusual transmembrane G-protein coupled receptor in that it is activated by serine protease cleavage of its extracellular N-terminus to expose an agonist peptide ligand, which is tethered to the receptor itself. Synthetic peptides containing the agonist motif, such as SFLLRN for human PAR-1, are capable of causing full receptor activation. We have probed the possible bioactive conformations of thrombin receptor-activating peptides (TRAPs) by systematic introduction of certain conformational perturbations, involving alpha-methyl, ester Psi(COO), and reduced-amide Psi(CH2N) scans, into the minimum-essential agonist sequence (SFLLR) to probe the importance of the backbone conformation and amide NH hydrogen bonding. We performed extensive conformational searches of representative pentapeptides to derive families of putative bioactive structures. In addition, we employed H-1 NMR and circular dichroism (CD) to characterize the conformational disposition of certain pentapeptide analogues experimentally. Activation of platelet aggregation by our pentapeptide analogues afforded a structure-function correlation for PAR-1 agonist activity. This correlation was assisted by PAR-1 receptor binding data, which gauged the affinity of peptide ligands for the thrombin receptor independent of a functional cellular response derived from receptor activation (i.e. a pure molecular recognition event). Series of alanine-, proline-, and N-methyl-scan peptides were also evaluated for comparison. Along with the known structural features for PAR-1 agonist peptides, our work adds to the understanding of peptide topography relative to platelet functional activity and PAR-1 binding. The absolute requirement of a positively charged N-terminus for strong agonist activity was contradicted by the N-terminal hydroxyl peptide Psi(HO)S-FLLR-NH2. The amide nitrogen between residues 1 and 2 was found to be a determinant of receptor recognition and the carbonyl groups along the backbone may be involved in hydrogen bonding with the receptor. Position 3 (P3) of TRAP-5 is known to tolerate a wide variety of side chains, but we also found that the amide nitrogen at this position can be substituted by an oxygen, as in SF-Psi(COO)-LLR-NH2, without diminishing activity. However, this peptide bond is sensitive to conformational changes in that SFPLR-NH2 was active, whereas SF-NMeL-LR-NH2 was not. Additionally, we found that position 3 does not tolerate rigid spacers, such as 3-aminocyclohexane-1-carboxylic acid and 2-aminocycloalkane-1-carboxylic acid, as analogues 1A, 1B, 2A, 2B, 3, 4, 5A and 5B lack agonist activity. On the basis of our results, we suggest that an extended structure of the agonist peptide is principally responsible for receptor recognition (i.e. binding) and that hydrophobic contact may occur between the side chains of the second (Phe) and fourth (Leu) residues (i.e. P2-P4 interaction). (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2353 / 2371
页数:19
相关论文
共 28 条
  • [21] Structure-activity studies of RGD-containing peptides derived from adhesive proteins. Application of structural criteria evaluated from bioactive synthetis RGD peptide analogues
    Kostidis, S.
    Thanou, E.
    Tsoukatos, D.
    Cung, M. T.
    Tsikaris, V.
    JOURNAL OF PEPTIDE SCIENCE, 2006, 12 : 182 - 182
  • [22] Design, Structure-Activity Relationships, and Computational Modeling Studies of a Series of α-Helix Biased, Ultra-Short Glucagon-like Peptide-1 Receptor Agonists
    Sawyer, Jonathon R.
    Audie, Joseph A.
    Swanson, Jon
    Diller, David
    Santiago, Solimar
    Gribkoff, Valentin K.
    Ackerman, Allison
    Hruby, Victor J.
    Gobbo, Gianpaolo
    Bellucci, Michael A.
    Glauser, William A.
    Pentelute, Brad L.
    Sawyer, Tomi K.
    MOLECULES, 2025, 30 (01):
  • [23] Structure-Activity Studies of Cysteine-Rich -Conotoxins that Inhibit High-Voltage-Activated Calcium Channels via GABAB Receptor Activation Reveal a Minimal Functional Motif
    Carstens, Bodil B.
    Berecki, Geza
    Daniel, James T.
    Lee, Han Siean
    Jackson, Kathryn A. V.
    Tae, Han-Shen
    Sadeghi, Mahsa
    Castro, Joel
    O'Donnell, Tracy
    Deiteren, Annemie
    Brierley, Stuart M.
    Craik, David J.
    Adams, David J.
    Clark, Richard J.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (15) : 4692 - 4696
  • [24] Exploration of structure-activity relationships at the two C-terminal residues of potent 11mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis
    Hague, Tasir S.
    Martinez, Rogelio L.
    Lee, Ving G.
    Riexinger, Douglas G.
    Lei, Ming
    Feng, Ming
    Koplowitz, Barry
    Mapelli, Claudio
    Cooper, Christopher B.
    Zhang, Ge
    Huang, Christine
    Ewing, William R.
    Krupinski, John
    PEPTIDES, 2010, 31 (07) : 1353 - 1360
  • [25] FURTHER INVESTIGATION INTO A DOPAMINE-D2 RECEPTOR MODEL - STRUCTURE-ACTIVITY STUDIES OF 2-BENZYL OR 3-BENZYL SUBSTITUTED 4-PROPYL-9-HYDROXYNAPHTHOXAZINE
    MINASKANIAN, G
    PAFF, ML
    SCHRADER, RR
    MAY, JM
    PECK, JV
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1993, 205 : 90 - MEDI
  • [26] Predictive models for GABAA/benzodiazepine receptor subtypes:: Studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [αxβ3γ2 (x = 1-3, 5, and 6)] via comparative molecular field analysis
    Huang, Q
    Liu, RY
    Zhang, PW
    He, XH
    McKernan, R
    Gan, T
    Bennett, DW
    Cook, JM
    JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (21) : 4130 - 4142
  • [27] Structure-Activity Relationships of Peptides Incorporating a Bioactive Reverse-Turn Heterocycle at the Melanocortin Receptors: Identification of a 5800-fold Mouse Melanocortin-3 Receptor (mMC3R) Selective Antagonist/Partial Agonist versus the Mouse Melanocortin-4 Receptor (mMC4R)
    Singh, Anamika
    Dirain, Marvin
    Witek, Rachel
    Rocca, James R.
    Edison, Arthur S.
    Haskell-Luevano, Carrie
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (07) : 2747 - 2763
  • [28] Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: Improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties
    Nair, AC
    Jayatilleke, P
    Wang, X
    Miertus, S
    Welsh, WJ
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (04) : 973 - 983